BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Rahardja S, Tan RYC, Sultana R, Leong FL, Lim EH. Efficacy, patterns of use and cost of Pertuzumab in the treatment of HER2+ metastatic breast cancer in Singapore: The National Cancer Centre Singapore experience. World J Clin Oncol 2020; 11(3): 143-151 [PMID: 32257845 DOI: 10.5306/wjco.v11.i3.143]
URL: https://www.wjgnet.com/2218-4333/full/v11/i3/143.htm
Number Citing Articles
1
Wei Fang Dai, Jaclyn M. Beca, Chenthila Nagamuthu, Ning Liu, Claire de Oliveira, Craig C. Earle, Maureen Trudeau, Rebecca E. Mercer, Kelvin K. W. Chan. Comparative Effectiveness and Safety of Pertuzumab and Trastuzumab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy for Treatment of Metastatic Breast CancerJAMA Network Open 2022; 5(2): e2145460 doi: 10.1001/jamanetworkopen.2021.45460
2
Silvia Falcon, Luis Riva, Christina Flores, Delphis Vera, Joseph Pinto, Henry Gomez. Neoadjuvant pertuzumab in non‑metastatic HER2‑positive breast tumors: Multicentric study in Peru (NeoHer)Molecular and Clinical Oncology 2022; 16(3) doi: 10.3892/mco.2022.2503
3
Sreeram V. Ramagopalan, Riccardo Pisoni, Lokendra Singh Rathore, Joshua Ray, Cormac Sammon. Association of Pertuzumab, Trastuzumab, and Docetaxel Combination Therapy With Overall Survival in Patients With Metastatic Breast CancerJAMA Network Open 2021; 4(1): e2027764 doi: 10.1001/jamanetworkopen.2020.27764